Tuesday, July, 16, 2019 04:31:15

Contribution By Shikha Sinha


Pfizer brings the development of DMD candidate Domagrozuma to a halt

Renowned New York-based pharma magnate Pfizer Inc., has reportedly axed two trials of its Domagrozuma antibody. As per sources, the candidate development has been halted on the grounds of its disappointing failure to meet the required efficacy targets. For the uninitiated, the anti-myostatin antibody is …

AstraZeneca phase III lupus-drug trial fails to meet primary goal

AstraZeneca along with its global biologics research and development business, MedImmune, has reportedly announced that the phase III trial for anifrolumab has failed to meet its primary goal. As per trusted sources, the complete evaluation of the data is likely to be conducted after the …